Search
Shattuck Labs Inc
STTKAdd to Watchlist
7.050USD
+0.540+8.29%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
532.85MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+8.29%
5 Days
+9.47%
1 Month
+46.88%
6 Months
+90.03%
Year to Date
+93.15%
1 Year
+745.93%
Key Figures
6.500Open
7.060High
908.94KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.20%Turnover Ratio
6.510Prev. Close
6.450Low
4.71MTurnover
LossP/E Static
5.56P/B
0.00%Div Yield TTM
-55.64%ROA
8.33052wk High
0.40Volume Ratio
-75.41MNet Profit
75.58MShares
-0.5642EPS TTM
1.11Beta
-61.04%ROE
0.71252wk Low
9.37%Amplitude
100.00%Gross Margin
532.85MMarket Cap
6.12Reward/Risk
5.82%Risk Rate
TradingKey Stock Score of Shattuck Labs Inc
Currency: USD Updated: 2026-07-02Key Insights
Shattuck Labs Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 79 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 15.80.In the medium term, the stock price is expected to remain stable.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Shattuck Labs Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Shattuck Labs Inc Highlights
StrengthsRisks
Shattuck Labs, Inc. is a biotechnology company. The Company is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The Company is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. It is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.
Growing
The company is in a growing phase, with the latest annual income totaling USD 1.00M.
Undervalued
The company’s latest PE is -12.50, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 50.41M shares, increasing 16.19% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 173.27K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.67.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
15.800
Target Price
+142.70%
Upside Space
Shattuck Labs Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Shattuck Labs Inc Info
Shattuck Labs, Inc. is a biotechnology company. The Company is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The Company is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. It is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.
Ticker SymbolSTTK
CompanyShattuck Labs Inc
CEOSchreiber (Taylor)
Websitehttps://www.shattucklabs.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Shattuck Labs Inc (STTK)?
The current price of Shattuck Labs Inc (STTK) is 7.05.
What is the symbol of Shattuck Labs Inc?
The ticker symbol of Shattuck Labs Inc is STTK.
What is the 52-week high of Shattuck Labs Inc?
The 52-week high of Shattuck Labs Inc is 8.33.
What is the 52-week low of Shattuck Labs Inc?
The 52-week low of Shattuck Labs Inc is 0.71.
What is the market capitalization of Shattuck Labs Inc?
The market capitalization of Shattuck Labs Inc is 532.85M.
Is Shattuck Labs Inc (STTK) currently rated as Buy, Hold, or Sell?
According to analysts, Shattuck Labs Inc (STTK) has an overall rating of Buy, with a price target of 15.80.
What is the Earnings Per Share (EPS TTM) of Shattuck Labs Inc (STTK)?
The Earnings Per Share (EPS TTM) of Shattuck Labs Inc (STTK) is -0.70.